Advertisement

Lexington molecular diagnostics firm Predictive Biosciences Inc. and Epigenomics AG, a German company focused on cancer treatment, have extended their licensing deal related to a biomarker for prostate cancer.

The original agreement, signed in April 2009, called for Predictive Biosciences to gain rights to develop a prostate cancer test using the GSTP1 prostate cancer biomarker; the company would also have optional rights to commercialize the test in the U.S.

SOURCE

Advertisement
Advertisement